Clinical Trials

Sigilon initiated a Phase 1/2 study in previously treated male patients with severe or moderately severe hemophilia A. The study is designed to evaluate the safety, tolerability, and preliminary efficacy of SIG-001 in adult male patients with severe or moderately severe hemophilia A without inhibitors. This trial remains on clinical hold and is not actively recruiting patients.

 

To learn more about the study, please visit the study listing on clinicaltrials.gov or on EudraCT.

 

Content